Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Survodutide and Tesofensine — mechanism, side effects, legal status, and pricing.
Survodutide is a dual GLP-1 / glucagon receptor agonist co-developed by Boehringer Ingelheim and Zealand Pharma. NOT FDA-approved; received FDA Breakthrough Therapy Designation in 2024 for non-cirrhotic MASH with moderate/advanced fibrosis. Phase 3 ongoing (SYNCHRONIZE in obesity/T2DM; LIVERAGE and LIVERAGE-Cirrhosis in MASH).
Tesofensine is a small-molecule triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine) — NOT a peptide. Originally developed by NeuroSearch for Parkinson's and Alzheimer's disease (which it failed to benefit) and repositioned for obesity by Saniona. Not FDA-approved in the US.
Survodutide
Tesofensine
Category
Legal Status
Mechanism
Side Effects
Contraindications
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Survodutide
Tesofensine
COA corpus from Disclosed Labs — independently tested batches only.
Survodutide
10
COAs
99.7%
Avg purity
4
Labs
Tesofensine
15
COAs
99.4%
Avg purity
6
Labs
Phase 2 MASH trial (Sanyal et al., NEJM 2024; 48 weeks, F1–F3 fibrosis): MASH resolution without worsening of fibrosis in 47% (2.4 mg), 62% (4.8 mg), and 43% (6.0 mg) vs 14% placebo. Phase 2 obesity trial reported ~19% weight loss at 46 weeks at the highest dose. Dose-dependent heart-rate elevation has been observed.
Pivotal Phase 2 (Astrup et al., Lancet 2008, n=203, 24 weeks, Denmark) showed placebo-subtracted weight loss of 4.5%, 9.2%, and 10.6% at 0.25, 0.5, and 1.0 mg/day — roughly twice orlistat at 0.5 mg. (The Lancet issued an expression of concern about that trial in 2013.) Saniona's Mexico partner Medix ran a Phase 3 registration study that met its primary endpoint; Medix filed with COFEPRIS in May 2023 with supplemental data submitted in 2024. As of April 2026 a final Mexican approval decision is still pending — the commonly repeated '2022 Mexico approval' claim is inaccurate. Tesomet (tesofensine + metoprolol, intended to blunt cardiovascular signal) is in development for hypothalamic obesity and Prader-Willi syndrome.
Survodutide and Tesofensine are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Lab Testing
Disclosed Labs